The studies will focus on the parkinson’s-implicated protein alpha-synuclein.
Amicus chief scientific officer David Lockhart said that they are honored to receive this grant from the MJFF, which will help us further develop their novel treatment for parkinson’s disease.
"The targeted compounds that we have discovered have shown promising effects in initial animal studies, and we are delighted to be working together with the MJFF and Chesselet to advance our lead compound into advanced preclinical studies," Lockhart said.
Amicus chairman and CEO John Crowley said that they appreciate MJFF’s backing of their pharmacological chaperone technology and believe this grant further demonstrates the strong scientific capabilities at Amicus.